

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently amended) A method of treating HPV infection comprising administering an effective amount of a nucleic acid molecule to a patient in need thereof, wherein said nucleic acid molecule inhibits expression associated with HPV replication, ~~and~~ wherein said nucleic acid molecule comprises double-stranded RNA or encodes a nucleic acid comprising double-stranded RNA, and wherein at least one strand of said double-stranded RNA comprises a sequence that is complementary to nucleotides 129 to 147 of SEQ ID NO:85.
- 2-3. (Cancelled).
4. (Original) The method of claim 1, wherein said nucleic acid molecule is administered topically.
5. (Original) The method of claim 4, wherein said nucleic acid molecule is administered topically to a portion of the genital organ of said patient.
6. (Original) The method of claim 4, wherein said nucleic acid molecule is administered topically to cervical tissue of said patient.
- 7-10. (Cancelled).
11. (Original) The method of claim 1, wherein said patient suffers from cervical intraepithelial dysplasia (CIN).

12. (Original) The method of claim 11, wherein said CIN is CIN I or mild dysplasia.
13. (Original) The method of claim 11, wherein said CIN is CIN II or moderate to marked dysplasia.
14. (Original) The method of claim 11, wherein said CIN is CIN III or severe dysplasia to carcinoma-in-situ.
15. (Original) The method of claim 14, wherein said carcinoma-in-situ is localized to the intraepithelial tissue or the superficial layer of the cervix.
- 16-19. (Cancelled).
20. (Currently amended) A method for treating a mammal having cells infected with HPV, said method comprising administering a nucleic acid molecule to said mammal under conditions wherein the number of said cells infected with said HPV is reduced, wherein said nucleic acid molecule comprises a sequence complementary to ~~a nucleotide sequence of said HPV~~ nucleotides 129 to 147 of SEQ ID NO:85, and wherein said nucleic acid comprises double-stranded RNA molecule or encodes a nucleic acid comprising double-stranded RNA.
21. (Original) The method of claim 20, wherein said mammal is a non-human, immunodeficient mammal, and wherein said cells are human cells.
22. (Original) The method of claim 20, wherein said mammal is a nude or SCID mouse.
23. (Original) The method of claim 20, wherein said mammal is a human.

24. (Original) The method of claim 20, wherein said cell is a skin cell or epithelial cell.
25. (Cancelled).
26. (Original) The method of claim 20, wherein said nucleic acid molecule is administered topically to said mammal.
27. (Original) The method of claim 26, wherein said nucleic acid molecule is administered topically to a portion of the genital organ of said mammal.
28. (Original) The method of claim 26, wherein said nucleic acid molecule is administered topically to cervical tissue of said mammal.
- 29-30. (Cancelled).
31. (Original) The method of claim 20, wherein the number of said cells infected with said HPV is reduced by at least 25 percent.
32. (Original) The method of claim 20, wherein the number of said cells infected with said HPV is reduced by at least 50 percent.
33. (Original) The method of claim 20, wherein the number of said cells infected with said HPV is reduced by at least 75 percent.
- 34-37. (Cancelled).
38. (Original) The method of claim 20, wherein said cells infected with said HPV contain non-integrated HPV nucleic acid.

39. (Original) The method of claim 20, wherein said cells infected with said HPV contain replicating HPV.

40-67. (Cancelled).